Lupin gets USFDA nod to market generic product
The company has received approval from the United States Food and Drug Administration (FDA) to market the generic version of Bausch Health Americas' Jublia topical solution, the Mumbai-based drug maker said in a regulatory filing. Drug major Lupin on Thursday said it has received approval from the US health regulator to market Efinaconazole topical solution, used to treat fungal toenail infections, in the American market. The company has received approval from the United States Food and Drug Administration (FDA) to market the generic version of Bausch Health Americas' Jublia topical solution, the Mumbai-based drug maker said in a regulatory filing. The product will be manufactured at the company's facility in Pithampur, it added. estimated annual sales of USD 274 million in the US.
Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!
